St. Jude Medical Inc.’s neurostimulation unit got a boost this week with two new US FDA approvals.
The first approval, announced Oct. 4, went to spinal cord stimulation system BurstDR, which is used to treat chronic pain...
St. Jude Neurostimulation Products Get US Thumbs Up
St. Jude Medical announced important US FDA approvals for neuromodulation devices to treat chronic pain, Parkinson’s disease and essential tremor.
More from Approvals
• By
Medicare beneficiaries with tricuspid regurgitation will now have access to an innovative treatment from Abbott that offers a minimally invasive alternative to open-heart surgery.
• By
Research recently published in JAMA Internal Medicine found that the FDA met its review timeline goals for the majority of breakthrough devices – but also revealed some apparent shortcomings in safety data supporting the submissions.
• By
The FDA's new Commissioner’s National Priority Voucher program aims to expedite drug approvals significantly. Device firms like XVIVO advocate for a similar initiative for devices, emphasizing the potential for faster reviews and improved patient access to lifesaving technologies.
• By
A recent approval from the US FDA allowing Boston Scientific to broaden its labeling for its pulse field ablation system means more patients with one type of AFib will have access to a promising new treatment.